文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.

作者信息

Rizzo Alessandro

机构信息

Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico "Don Tonino Bello", I.R.C.C.S. Istituto Tumori "Giovanni Paolo II,", Viale Orazio Flacco 65, Bari, 70124, Italy.

出版信息

Br J Cancer. 2022 Nov;127(8):1381-1382. doi: 10.1038/s41416-022-01929-w. Epub 2022 Sep 5.

DOI:10.1038/s41416-022-01929-w
PMID:36064585
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9553978/
Abstract
摘要

相似文献

[1]
Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.

Br J Cancer. 2022-11

[2]
Response to: Identifying optimal first-line treatment for advanced non-small cell lung carcinoma with high PD-L1 expression: a matter of debate.

Br J Cancer. 2022-11

[3]
[Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].

Zhongguo Fei Ai Za Zhi. 2021-9-20

[4]
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

J Clin Oncol. 2018-1-16

[5]
Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?

Clin Lung Cancer. 2016-9

[6]
PD-L1 expression and EGFR status in advanced non-small-cell lung cancer patients receiving PD-1/PD-L1 inhibitors: a meta-analysis.

Future Oncol. 2019-5-1

[7]
Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression.

J Cancer Res Clin Oncol. 2021-1

[8]
Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.

Cancer Cytopathol. 2018-2-7

[9]
[Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].

Zhongguo Fei Ai Za Zhi. 2019-7-20

[10]
[Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or 
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].

Zhongguo Fei Ai Za Zhi. 2021-3-20

引用本文的文献

[1]
The efficacy and safety of immune combination therapy in patients with driver gene-negative non-small cell lung cancer with liver metastasis: a systematic review and network meta-analysis.

BMC Cancer. 2025-8-18

[2]
Feasibility of machine learning-based modeling and prediction to assess osteosarcoma outcomes.

Sci Rep. 2025-5-19

[3]
Unraveling the anti-tumor effects of midazolam in non-small cell lung cancer through the lncRNA XLOC_010706/miR-520d-5p/STAT3/autophagy pathway.

Sci Rep. 2025-5-14

[4]
Case Report: Second-line favourable effect of pembrolizumab plus chemotherapy in a patient with metastatic hepatoid adenocarcinoma of the stomach.

Front Pharmacol. 2025-4-1

[5]
A novel tumor-associated macrophage risk signature predicts prognosis and immunotherapy response in lung adenocarcinoma.

Am J Cancer Res. 2025-3-15

[6]
Enhancement of Prognostic Outcomes in Stage III Non-Small Cell Lung Cancer: A Retrospective Study on Neoadjuvant Immuno-Chemotherapy Followed by Definitive Chemo-Radiotherapy.

Transl Oncol. 2025-6

[7]
Tumor-derived immunoglobulin-like transcript 3 inhibition reshapes the immunosuppressive tumor microenvironment and potentiates programmed cell death ligand 1 blockade immunotherapy in lung adenocarcinoma.

Transl Oncol. 2025-6

[8]
Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs.

Int J Nanomedicine. 2025-3-19

[9]
Evaluation of a novel ensemble model for preoperative ovarian cancer diagnosis: Clinical factors, O-RADS, and deep learning radiomics.

Transl Oncol. 2025-4

[10]
A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer.

Sci Rep. 2025-2-27

本文引用的文献

[1]
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020.

J Natl Compr Canc Netw. 2019-12

[2]
The biology and management of non-small cell lung cancer.

Nature. 2018-1-24

[3]
Network meta-analysis: an introduction for clinicians.

Intern Emerg Med. 2017-2

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索